Your browser doesn't support javascript.
loading
Infection with chikungunya virus confers heterotypic cross-neutralizing antibodies and memory B-cells against other arthritogenic alphaviruses predominantly through the B domain of the E2 glycoprotein.
Powers, John M; Lyski, Zoe L; Weber, Whitney C; Denton, Michael; Streblow, Magdalene M; Mayo, Adam T; Haese, Nicole N; Nix, Chad D; Rodríguez-Santiago, Rachel; Alvarado, Luisa I; Rivera-Amill, Vanessa; Messer, William B; Streblow, Daniel N.
Afiliación
  • Powers JM; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, United States of America.
  • Lyski ZL; Department of Molecular Microbiology and Immunology, Oregon Health and Science University, Portland, Oregon, United States of America.
  • Weber WC; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, United States of America.
  • Denton M; Department of Molecular Microbiology and Immunology, Oregon Health and Science University, Portland, Oregon, United States of America.
  • Streblow MM; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, United States of America.
  • Mayo AT; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, United States of America.
  • Haese NN; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, United States of America.
  • Nix CD; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, United States of America.
  • Rodríguez-Santiago R; Department of Molecular Microbiology and Immunology, Oregon Health and Science University, Portland, Oregon, United States of America.
  • Alvarado LI; Ponce Health Sciences University/ Ponce Research Institute, Ponce, Puerto Rico.
  • Rivera-Amill V; Ponce Health Sciences University/ Ponce Research Institute, Ponce, Puerto Rico.
  • Messer WB; Ponce Health Sciences University/ Ponce Research Institute, Ponce, Puerto Rico.
  • Streblow DN; Department of Molecular Microbiology and Immunology, Oregon Health and Science University, Portland, Oregon, United States of America.
PLoS Negl Trop Dis ; 17(3): e0011154, 2023 03.
Article en En | MEDLINE | ID: mdl-36913428
ABSTRACT
Infections with Chikungunya virus, a mosquito-borne alphavirus, cause an acute febrile syndrome often followed by chronic arthritis that persists for months to years post-infection. Neutralizing antibodies are the primary immune correlate of protection elicited by infection, and the major goal of vaccinations in development. Using convalescent blood samples collected from both endemic and non-endemic human subjects at multiple timepoints following suspected or confirmed chikungunya infection, we identified antibodies with broad neutralizing properties against other alphaviruses within the Semliki Forest complex. Cross-neutralization generally did not extend to the Venezuelan Equine Encephalitis virus (VEEV) complex, although some subjects had low levels of VEEV-neutralizing antibodies. This suggests that broadly neutralizing antibodies elicited following natural infection are largely complex restricted. In addition to serology, we also performed memory B-cell analysis, finding chikungunya-specific memory B-cells in all subjects in this study as remotely as 24 years post-infection. We functionally assessed the ability of memory B-cell derived antibodies to bind to chikungunya virus, and related Mayaro virus, as well as the highly conserved B domain of the E2 glycoprotein thought to contribute to cross-reactivity between related Old-World alphaviruses. To specifically assess the role of the E2 B domain in cross-neutralization, we depleted Mayaro and Chikungunya virus E2 B domain specific antibodies from convalescent sera, finding E2B depletion significantly decreases Mayaro virus specific cross-neutralizing antibody titers with no significant effect on chikungunya virus neutralization, indicating that the E2 B domain is a key target of cross-neutralizing and potentially cross-protective neutralizing antibodies.
Asunto(s)

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Virus Chikungunya / Fiebre Chikungunya Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: PLoS Negl Trop Dis Asunto de la revista: MEDICINA TROPICAL Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Virus Chikungunya / Fiebre Chikungunya Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: PLoS Negl Trop Dis Asunto de la revista: MEDICINA TROPICAL Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos